March is Kidney Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the landscape of kidney cancer treatment and care. We want to highlight recent discoveries in the field and raise awareness about the significance of early diagnosis, multidisciplinary management, and the pivotal role of technological innovation in combating kidney cancer.
Kidney cancer is one of the most common cancers globally which has a low survival rate and poor prognosis. Renal cell carcinoma (RCC) is the predominant of kidney cancer with further challenges as over 30% of RCC patients diagnosed with metastatic RCC. This underscores the urgency for early detection and intervention strategies to improve patient outcomes.
Traditional forms of treatment include surgical intervention such as nephrectomy or partial nephrectomy. However, advancements in systemic treatments and therapies are crucial for patients diagnosed with advanced stages of the disease. At the forefront of research, new targeted therapies and immunotherapies are offering promising avenues for improving survival rates and quality of life for patients with advanced RCC. Examples of therapeutic strategies includes first-line treatment options and the development of innovative immunotherapies. The combination of targeted therapies and immune checkpoint inhibitors has provided promising results which leads to more personalized treatment plans, improving survival rates and patient outcomes.
The goal of this Research Topic is to generate a discussion of the current research in kidney cancer and renal cell carcinoma (RCC), fostering a comprehensive understanding of the complexities and innovations within the field. We aim to bring together leading researchers, clinicians, and stakeholders to share insights and advancements that are driving the future of kidney cancer treatment. By focusing on the latest developments in molecular biology, early diagnostic techniques, and novel therapeutic strategies—including targeted therapies and groundbreaking immunotherapies—this platform seeks to highlight both the challenges and opportunities in addressing RCC.
We welcome Original Research, Review, Systematic Reviews, Case Reports and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: kidney cancer, oncology, cancer, treatment, diagnosis, awareness
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
